Huons Global Receives Clinical Trial Approval for 'Hutox' in China
[Asia Economy Reporter Geum Bo-ryeong] Huons Global announced on the 4th that it has received approval for a clinical trial plan for the therapeutic biologic drug 'Botulinum toxin type A injection' from China's CDE (Center for Drug Evaluation).
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The target condition is moderate to severe glabellar lines. Huons Global explained the purpose of the clinical trial as "to evaluate the efficacy and safety of HUTOX injection in individuals confirmed to have moderate to severe glabellar lines."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
